369 related articles for article (PubMed ID: 9740538)
1. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
2. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
3. Cerivastatin.
Cheng-Lai A
Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
5. [A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia].
Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
Rev Med Interne; 1999 Aug; 20 Suppl 3():393s-398s. PubMed ID: 10480191
[TBL] [Abstract][Full Text] [Related]
6. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Stein E
Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
[TBL] [Abstract][Full Text] [Related]
7. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Stein E
Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154
[TBL] [Abstract][Full Text] [Related]
8. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G
Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153
[TBL] [Abstract][Full Text] [Related]
9. Cerivastatin.
McClellan KJ; Wiseman LR; McTavish D
Drugs; 1998 Mar; 55(3):415-20; discussion 421-2. PubMed ID: 9530546
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L
Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644
[TBL] [Abstract][Full Text] [Related]
11. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
Clin Ther; 1998; 20(3):539-48. PubMed ID: 9663369
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
[TBL] [Abstract][Full Text] [Related]
14. Cerivastatin for lowering lipids.
Adams SP; Tiellet N; Alaeiilkhchi N; Wright JM
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012501. PubMed ID: 31981471
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of a statine of the most recent generation].
Notarbartolo A; Barbagallo CM
Ital Heart J Suppl; 2001 Mar; 2(3):230-4. PubMed ID: 11307781
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Renders L; Mayer-Kadner I; Koch C; Schärffe S; Burkhardt K; Veelken R; Schmieder RE; Hauser IA
Nephrol Dial Transplant; 2001 Jan; 16(1):141-6. PubMed ID: 11209008
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical pharmacology of cerivastatin.
Bischoff H; Heller AH
Am J Cardiol; 1998 Aug; 82(4B):18J-25J. PubMed ID: 9737642
[TBL] [Abstract][Full Text] [Related]
20. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
